GreenWood, Inc., an integrated operations, maintenance and construction solutions provider, celebrates reaching 5.5 million safe work hours at their Merck project site in Elkton, Virginia. The major safety milestone was achieved across a 30-year continuous work relationship between GreenWood and Merck. GreenWood’s team provides Merck with various construction related services. This Merck location produces vaccines in a facility covering more than one million square feet and has been operational for over seven decades.
At the center of this significant accomplishment is GreenWood’s “Always Aware” safety program which emphasizes safe work practices for individuals and employee teams at all times. The program integrates into the Merck safety standards where prevention of incidents, accidents and injuries is an ongoing priority.
“These milestones are reached only by having a safety mindset through employee engagement at all times,” says Kevin Crittendon, Vice President of GreenWood. “When we do that consistently, we all enjoy celebrating the accomplishments of having zero incidents.”
About GreenWood, Inc.
GreenWood provides integrated maintenance, operations and construction solutions designed to extend the life of critical assets, influence operational efficiencies and deliver bottom line improvements for plants and facilities throughout the Southeast and Mid-Atlantic. We operate under a “Customer-Centered” philosophy where safety performance is always first and our flexibility to respond to customer needs is an ongoing priority as it has been for over 30 years. GreenWood, Inc. is certified as a women-owned business by the Women’s Business Enterprise National Council (WBENC). For more information, visit www.GreenWoodInc.com.
For more than 125 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten people and animals – including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases – as we aspire to be the premier research-intensive biopharmaceutical company in the world. For more information, visit www.merck.com.